Immunovant, Inc. (NASDAQ:IMVT) Shares Purchased by Tyro Capital Management LLC

Tyro Capital Management LLC grew its position in shares of Immunovant, Inc. (NASDAQ:IMVT) by 0.6% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 252,149 shares of the company’s stock after acquiring an additional 1,529 shares during the period. Immunovant comprises about 2.3% of Tyro Capital Management LLC’s holdings, making the stock its 13th largest position. Tyro Capital Management LLC’s holdings in Immunovant were worth $7,189,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of IMVT. KBC Group NV lifted its holdings in Immunovant by 46.2% in the 3rd quarter. KBC Group NV now owns 1,936 shares of the company’s stock worth $55,000 after buying an additional 612 shares in the last quarter. Quest Partners LLC boosted its holdings in Immunovant by 216.7% in the second quarter. Quest Partners LLC now owns 2,610 shares of the company’s stock valued at $69,000 after purchasing an additional 1,786 shares during the last quarter. Assetmark Inc. grew its stake in Immunovant by 73.8% during the 3rd quarter. Assetmark Inc. now owns 2,891 shares of the company’s stock valued at $82,000 after purchasing an additional 1,228 shares in the last quarter. Headlands Technologies LLC purchased a new stake in Immunovant during the 2nd quarter worth approximately $77,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Immunovant by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,294 shares of the company’s stock valued at $148,000 after purchasing an additional 934 shares in the last quarter. 47.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IMVT has been the subject of a number of research analyst reports. Raymond James restated an “outperform” rating and issued a $36.00 price target on shares of Immunovant in a research note on Thursday, October 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunovant in a research report on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and set a $51.00 target price on shares of Immunovant in a report on Friday, November 8th. Finally, Oppenheimer boosted their price target on Immunovant from $47.00 to $53.00 and gave the company an “outperform” rating in a report on Wednesday, October 9th. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $47.89.

Immunovant Trading Down 4.5 %

IMVT stock opened at $27.59 on Friday. The stock’s fifty day moving average is $28.93 and its two-hundred day moving average is $28.75. Immunovant, Inc. has a 1 year low of $24.61 and a 1 year high of $45.58.

Immunovant (NASDAQ:IMVT) last posted its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). During the same quarter in the previous year, the business earned ($0.45) EPS. Equities analysts anticipate that Immunovant, Inc. will post -2.73 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Mark S. Levine sold 3,650 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $25.45, for a total value of $92,892.50. Following the completion of the transaction, the insider now owns 319,228 shares of the company’s stock, valued at approximately $8,124,352.60. This trade represents a 1.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Peter Salzmann sold 4,460 shares of the business’s stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $29.56, for a total transaction of $131,837.60. Following the sale, the chief executive officer now directly owns 1,003,884 shares in the company, valued at approximately $29,674,811.04. This trade represents a 0.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 77,659 shares of company stock valued at $2,096,890 in the last three months. 5.90% of the stock is currently owned by corporate insiders.

About Immunovant

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.